Feasibility Studies to Develop Technology and Methods for Genomics, Population Genomics and ELSI (R21)

Submission Date: February 16, 2008

Direct costs are limited to $300,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

The purpose is to support feasibility studies to conduct innovative high risk/high payoff research related to genomics, including analysis of genome structure and function, genetic variation, population genomics, and ELSI (ethical, legal, and social implications).

For more information, please visit the NIH grants webpage.